Data Reveals JAK Inhibitor Traction for RA
Therapy Watch released data-which uses real-time patient record form data to monitor healthcare market dynamics-proposing that JAK inhibitors have made a strong impression on the Rheumatoid Arthritis (RA) market across France, Germany, Italy, Spain, and the UK (the EU5).
According to the study, JAK inhibitors have expanded their market share across the EU5 from 3.1% in Q3 2017 to 15.6% in Q2 2018.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
